11 studies found for:    s0816
Show Display Options
Rank Status Study
1 Recruiting S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
Conditions: Lymphoma;   Nonneoplastic Condition
Interventions: Biological: bleomycin sulfate;   Biological: filgrastim;   Drug: ABVD regimen;   Drug: BEACOPP regimen;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vinblastine sulfate;   Drug: vincristine sulfate
2 Terminated Biomarkers in Blood Samples From Patients With HIV Infection and Stage III or Stage IV Hodgkin Lymphoma Undergoing Chemotherapy
Conditions: Lymphoma;   Nonneoplastic Condition
Interventions: Genetic: DNA analysis;   Genetic: RNA analysis;   Other: laboratory biomarker analysis
3 Not yet recruiting Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations
Condition: Platinum Sensitive Relapsed Ovarian Cancer
Interventions: Drug: OLAPARIB;   Other: PLACEBO
4 Completed
Has Results
RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial
Condition: Atrial Fibrillation
Interventions: Drug: dabigatran dose 1;   Drug: dabigatran dose 2
5 Terminated Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia
Conditions: Acute Leukemias of Ambiguous Lineage;   Acute Undifferentiated Leukemia;   Angioimmunoblastic T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Small Intestine Lymphoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: dexrazoxane hydrochloride;   Drug: doxorubicin hydrochloride;   Drug: obatoclax mesylate;   Drug: liposomal vincristine sulfate;   Other: pharmacological study;   Other: laboratory biomarker analysis
6 Active, not recruiting OSCA - Olaparib Standard of CAre Study
Condition: Platinum-sensitive Recurrent Serous Ovarian Cancer
Intervention: Other: Data Collection
7 Active, not recruiting Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Conditions: Platinum Sensitive;   BRCA Mutated;   Relapsed Ovarian Cancer;   Following Complete or Partial Response to Platinum Based Chemotherapy
Interventions: Drug: Olaparib 300mg tablets;   Drug: Placebo to match olaparib 300mg
8 Completed
Has Results
Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium;   Drug: placebo
9 Completed
Has Results
Effect of Rowachol on Prevention of Postcholecystectomy Syndrome
Condition: Postcholecystectomy Syndrome
Interventions: Drug: Rowachol;   Drug: Placebo
10 Completed
Has Results
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate
Conditions: Atrial Fibrillation;   Stroke
Interventions: Drug: warfarin;   Drug: Dabigatran dose 1;   Drug: Dabigatran dose 2
11 Recruiting Cancer Genetics Hereditary Cancer Panel Testing
Condition: Hereditary Breast and Ovarian Cancer
Interventions: Other: Questionnaires;   Other: Blood Draw and Baseline Questionnaire

Indicates status has not been verified in more than two years